Latest & greatest articles for risperidone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on risperidone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on risperidone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for risperidone

101. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: a retrospective analysis using the Saskatchewan health linkable databases

Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: a retrospective analysis using the Saskatchewan health linkable databases Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: a retrospective analysis using the Saskatchewan health linkable databases (...) Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: a retrospective analysis using the Saskatchewan health linkable databases Albright P S, Livingstone S, Keegan D L, Ingham M, Shrikhande S, Le Lorier J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods

NHS Economic Evaluation Database.1996

102. Risperidone: efficacy and safety

Risperidone: efficacy and safety Risperidone: efficacy and safety Risperidone: efficacy and safety Umbricht D, Kane J M Authors' objectives To review the evidence for the efficacy and effectiveness of risperidone in persons with schizophrenia. Searching MEDLINE and PsycLIT were searched from 1988, and references in retrieved articles were searched for additional studies. Study selection Study designs of evaluations included in the review The included studies were double-blind trials comparing (...) risperidone with another antipsychotic or a placebo. The duration of the trials ranged from 4 to 12 weeks. Specific interventions included in the review The included studies compared risperidone to either another antipsychotic or a placebo. Risperidone was given in doses ranging from 2 to 20 mg daily. The other antipsychotics studied were haloperidol, perphenazine and clozapine at daily doses ranging from 2 to 20 mg, 16 to 48 mg, and 400 mg, respectively. Participants included in the review Patients

DARE.1995

103. Risperidone immediate release complete Drug Approval Package (all reviews)

Risperidone immediate release complete Drug Approval Package (all reviews) Oregon Health & Science University OHSU Digital Commons FDA Drug Approval Documents December 1993 Risperidone immediate release complete Drug Approval Package (all reviews) United States. Food and Drug Administration. Follow this and additional works at: http://digitalcommons.ohsu.edu/fdadrug This Article is brought to you for free and open access by OHSU Digital Commons. It has been accepted for inclusion in FDA Drug (...) Approval Documents by an authorized administrator of OHSU Digital Commons. For more information, please contact champieu@ohsu.edu. Recommended Citation United States. Food and Drug Administration., "Risperidone immediate release complete Drug Approval Package (all reviews)" (1993). FDA Drug Approval Documents. 19. http://digitalcommons.ohsu.edu/fdadrug/190- PDF page 1 of 686PDF page 2 of 686("~ DEPARTMENT OF HEALTH &. HUMAN SERVICES ,~~ Public Health Service Food and Drug Administration Rockville MD

FDA Drug Approval Documents (via OHSU)1993